Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Obesity 9 Endometrial Neoplasms 4 Prostatic Neoplasms 2 Overweight 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Opioid-Related Disorders 1 Metabolic Syndrome 1 Lymphoma, Follicular 1 Insulin Resistance 1 Inflammation 1 Hyperplasia 1 Dyslipidemias 1 Colorectal Neoplasms 1

Interventions

anamorelin 2 Caloric Restriction 2 Urine Specimen Collection 1 Tirzepatide 1 Sampling Studies 1 Resistance Training 1 Psychology, Positive 1 Population Groups 1 Olanzapine 1 Nutrition Assessment 1 Mirtazapine 1 Methods 1 Metformin 1 Megestrol Acetate 1 Inositol 1 Growth Differentiation Factor 15 1 Diet, Reducing 1 Diet Therapy 1 Diet 1 Counseling 1 Cognitive Behavioral Therapy 1 Breast Implants 1 Blood Specimen Collection 1 Biopsy 1 2,2,2',4'-tetrachloroacetophenone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Weight Loss × Tirzepatide × 1 year × Clear all

NCT06518837 2026-01-21

FITWISE

Rutgers, The State University of New Jersey

Phase 2 Recruiting

Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡